Skip to main content

Pranshu Mohindra, MD, MBBS

Academic Title:

Assistant Professor

Primary Appointment:

Radiation Oncology

Location:

22 S. Greene St., Baltimore, Maryland-21201

Phone (Primary):

410-328-7617

Phone (Secondary):

410-328-6080

Fax:

410-328-5279

Education and Training

Education

  • 1997 - 2003: M.B.B.S, Dr D Y Patil Medical College, University of Mumbai, India Date of Degree: 12/2003
  • 2004 - 2007: M.D., Tata Memorial Hospital, University of Mumbai, India Date of Degree: 02/2008
    MD Dissertation: Low dose Total Body Irradiation in cases of Low Grade Non-Hodgkin’s Lymphoma: Response evaluation & Immunological-Radiobiological assessment of mechanism.
    Advisor: Dr. Mary Ann Muckaden

Post Graduate Education and Training

  • 2002 - 2003: Internship: Dr D Y Patil Medical College, University of Mumbai, India
  • 2004 - 2007: Residency: Radiation Oncology, Tata Memorial Hospital, University of Mumbai, India
  • 2006 - 2007: Professional Diploma in Clinical Research: Catalyst Clinical Services Pvt. Ltd., India (Correspondence Course)
  • 2007 - 2008: Senior Residency (Fellow): Radiation Oncology Tata Memorial Hospital, India
  • 2009 - 2009: Global Academic Research Associate (Post-doctoral fellow): University of Texas MD. Anderson Cancer Center, Houston, Texas, USA,Supervisor: Dr. S. Krishnan
  • 2009 - 2010: Clinical Fellow: Radiation Oncology (Head and Neck Cancer)Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Canada, Program Director: Dr. Charles Catton
  • 2010 - 2014: Residency: Radiation Oncology University of Wisconsin Hospital and Clinics, Madison, WI, Program Director: Dr. Kristin A Bradley

Certifications

  • 2003 M.B.B.S, University of Mumbai, India
  • 2008 M.D. (Radiotherapy), University of Mumbai, India
  • 2015 American Board of Radiology- Radiation Oncology

Biosketch

Soon after completion of a second residency in radiation oncology in the U.S. (previously board certified in radiation oncology from the prestigious Tata Memorial Center, University of Mumbai, India in India and fellowship trained for head-neck cancer radiation oncology at the Princess Margaret Hospital, University of Toronto, Canada), Dr. Mohindra joined the Department of Radiation Oncology at the University of Maryland School of Medicine, Baltimore in July 2014 as an assistant professor in a clinician-scientist role. His primary area of clinical and research interest is in thoracic/lung, gynecological and hemato-lymphoid malignancies. 

Dr. Mohindra has received several academic excellence, research and travel awards during his residency including the 2014 Radiological Society of North America (RSNA) Roentgen Resident/Fellow Award for outstanding radiologic research and the 2014 American Society for Radiation Oncology (ASTRO) Resident Digital Poster Discussion Award in the Biology category. He also served as the Chief resident for the year 2013-14. 

Dr. Mohindra has active involvement in multi-disciplinary collaborative research endeavors including prospective clinical protocols with special emphasis on early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques. He currently serve as national PI of two NCI-sponsored phase-I clinical trials; one of which was career development project team award evaluating a novel DNA repair pathway inhibitor with whole brain radiotherapy (WBRT) in patients with brain metastases from NSCLC (CIRB and CTEP approved, NCT02589522). The other phase-I clinical trial evaluating combination of oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) with WBRT in brain metastases (CTEP approved, CIRB review pending). He is also a co-PI for an ongoing phase Ia-b dose escalation study evaluating the safety and efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) with concomitant capecitabine for resectable pancreatic carcinoma (NCT01918644) and a co-investigator on an ongoing phase II clinical study evaluating the role of pulsed-reduced dose-rate (PRDR) radiation therapy with bevacizumab for recurrent highgrade gliomas (University of Wisconsin Hospital and Clinics, NCT01743950). He was also recently appointed as national Radiation Oncology Co-Chair on an Alliance for Clinical Trials in Oncology Clinical trial (ALLIANCE A041501) that is currently under development.

Dr. Mohindra is an appointed member of the ACR Radiation Oncology In-Training (TXITTM) Exam committee developing examination questions for residents in radiation oncology. He served as an appointed member of committees within the American Society for Radiation Oncology (ASTRO) and Alliance for Clinical Trials in Oncology.

Research/Clinical Keywords

thoracic/lung cancers, gynecological malignancies, hemato-lymphoid malignancies, intensity modulated proton therapy (IMPT)/pencil beam scanning proton therapy, intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), Image-guided Brachytherapy.

Highlighted Publications

CONTRIBUTIONS TO SCIENCE

Contributions in Thoracic-Oncology: At my current institution, my area of clinical and research expertise is for thoracic malignancies. In my one and half year of faculty role, my research in thoracic oncology has yielded two full manuscripts, four manuscripts under review, three abstracts in 2015 ASTRO annual meeting and two additional submissions for 2016 ASTRO meeting, four of which are resident mentored applications. I currently serve as the currently serve as national PI of a NCI-sponsored phase-I clinical trial (career development project team award) evaluating a novel DNA repair pathway inhibitor with whole brain radiotherapy (WBRT) in patients with brain metastases from NSCLC (CIRB and CTEP approved, NCT02589522). I have been appointed to serve as a contributor to the thoracic-section of the ACR In-Training Exam in Radiation Oncology since 2015.  

  1. Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM.Dose Limiting Toxicity Following Hypofractionated Dose-Escalated Radiotherapy In Non-Small Cell Lung Cancer. JCO 2013 Oct. 21 [Epub ahead of print]. PMID: 24145340
  2. Murigi FN, Mohindra P, Hung C, Salimi S, Goetz W, Pavlovic R, Jackson IL, Vujaskovic Z. Dose Optimization Study of AEOL 10150 as a Mitigator of Radiation-Induced Lung Injury in CBA/J Mice. Radiat Res. 2015 Oct;184(4):422-32. Epub 2015 Sep 28. PMID: 26414508
  3. de Faria EB, Barrow KR, Ruehle BT, Parker JT, Swartz E, Taylor-Howell C, Kieta KM, Lees CJ, Sleeper MM, Dobbin T, Baron AD, Mohindra P, MacVittie TJ. The Evolving Mcart Multimodal Imaging Core: Establishing a Protocol for Computed Tomography and Echocardiography in the Rhesus Macaque to Perform Longitudinal Analysis of Radiation-Induced Organ Injury. Health Phys. 2015 Nov;109(5):479-92. PMID: 26425907.
  4. Bhooshan N, Edelman MJ, Nichols E, Vyfhuis M, Feliciano J, Burrows W, Suntharalingam M, D’Souza W, Vujaskovic Z, Feigenberg S, Mohindra P. Does Severe Radiation Pneumonitis (RP) Affect Clinical Outcomes in Non-Operable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Carboplatin/Paclitaxel (CP)-based Concurrent Chemoradiation Therapy (CRT)? IJROBP, 2015:93(3), Supplement, Page S151.
  5. Mohindra P, Barrow K, Kieta KM, Parker J, De Faria E, Taylor-Howell C, Dobbin T, Gibbs A, Farese AM, MacVittie TJ. Use of Computed Tomography (CT) scan to Assess Efficacy of Mitigators of Radiation-induced Lung Injury (RILI): A Rhesus Macaque Whole Thoracic Lung Irradiation (WTLI) Model. IJROBP, 2015:93(3), Supplement, Page E512.

Contributions in Gynecology-Oncology: Through the two radiation oncology residency trainings I have developed significant experience in the management of gynecological cancer. Utilizing the platform of this experience, I have helped initiate MRI-guided brachytherapy program for cervical cancer in the Department of Radiation Oncology, University of Maryland Medical Center. Further, I am now working towards establishing research expertise in the field of gynecology-oncology. I have been appointed to serve as a contributor to the Gyn-section of the 2017 ACR In-Training Exam in Radiation Oncology. I am also collaborating with the members within the Gynecology-Oncology group in developing our institutional database of gynecological cancers. I was also recently awarded access to the National Cancer Database for endometrial cancers. Analysis of this database has resulted in two first author abstract submissions to the upcoming ASTRO annual meeting in addition to another senior author submission with my colleague.

  1. Mishra S, Laskar S, Muckaden MA, Mohindra P, Shrivastava SK, Dinshaw KA. Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix. Journal of Cancer Research & Therapeutics. 2005 Oct; 1(4): 208-212. PMID: 17998655.
  2. Mohindra P, Kruser TJ, Gondi V, Thomas SR, McHaffie DR, Bradley KA. Papillary serous and clear cell adenocarcinoma of the uterus: A 10-year single-institution experience. IJROBP, 2011;81(2):Supplement, Pages S471-S472. Poster Presentation- ASTRO 53rd Annual Meeting 2011; Miami.
  3. Mohindra P, Bentzen SM, Scartoni D, Giacomelli I, Rao G, Roque DM, Hanna N, Nichols EM. Adjuvant Therapy for Locoregionally Advanced Endometrioid Adenocarcinoma (EA): Upfront Chemotherapy (UC) or Upfront Radiotherapy (UR)? Selected for poster presentation- ASTRO annual meeting 2016.
  4. Mohindra P, Bentzen SM, Giacomelli I, Scartoni D, Roque DM, Rao G, Hanna N, Nichols EM. Adjuvant Whole Pelvic Radiation Therapy (WPRT) for Endometrioid Adenocarcinoma (EA): 45 Gy or 50/50.4 Gy? Selected for poster presentation - ASTRO annual meeting 2016.
  5. Nichols EM, Bentzen SM, Scartoni D, Giacomelli I, Rao G, Roque DM, Hanna N, Mohindra P. Positive impact of radiation therapy in the management of uterine carcinosarcoma. Selected for oral presentation - ASTRO annual meeting 2016 and for Best of ASTRO 2016 meeting.

Contributions in Head-Neck Oncology: Through both my residencies in radiation oncology (India and the U.S.) and an additional 1-year dedicated clinical fellowship at the Princess Margaret Hospital (Toronto, Canada), head-neck cancer (HNC) has been an important area of clinical activities and research. HNC forms about 3% of all malignancies in the U.S. Radiation therapy plays a critical role in the management of HNC either adjuvant or definitive both with or without concurrent chemotherapy. With improving outcomes of patients with HNC, in part from the biological role of viral-induced malignancies, it is critical to evaluate institutional outcomes with advanced radiation techniques with the goal of reducing morbidity. I reviewed the institutional outcomes of patients with nasopharyngeal cancer at Tata Memorial Hospital, Mumbai and more recently at Univ. of Wisconsin, performed a comprehensive 20-year review of outcomes for patients with oropharyngeal cancer.

  1. Mohindra P, Urban E, Pagan JD, Geye HM, Patel VB, Bayliss RA, Bender ET, Harari PM. Selective omission of level V nodal coverage for patients with oropharynx cancer: Clinical validation of intensity modulated radiotherapy experience and dosimetric significance. Head Neck. 2014 Dec 1. [Epub ahead of print]. PMID: 25445257
  2. Morris ZS, Mohindra P, Kruser TJ. Combined chemo-radiation therapy in the treatment of squamous cell carcinoma of the head and neck; an evolving paradigm. Oncol Hematol Rev(US)., 2014;9:109-114.
  3. Hoffman MR, McCulloch TM, Mohindra P, Das R, Geurts M, Harari PM. Simulation study of high-dose-rate brachytherapy for early glottic cancer.  Brachytherapy. 2015 Nov 21. Epub ahead of print, PMID: 26614234

Contributions towards education in radiation oncology: Radiation Oncology continues to be one of the most sought after fields attracting the brightest medical students who often spend additional years of dedicated research in the field. However, fourth-year medical students (MS4s) have limited meaningful exposure to radiation oncology training programs and thus base their decision largely on a limited number of factors. The assessment of variables utilized by MS4s during the selection process has never formally been investigated. To gain perspective, which might be useful to training programs and future applicants, I was involved in publication of the first ever report that described the factors assessed by MS4s during the process of residency selection. As one of the founding members of the education sub-committee of the Association of Residents in Radiation Oncology (ARRO), we conducted a unique study assessing the factors involved in the job search and career planning both from the perspective of graduating residents and the hiring physicians. I developed multiple peer-reviewed educational presentations for the online educational resource through the ARRO. Further, I served as the institutional co-investigator for a multi-institutional introductory structured didactic radiation oncology curriculum for medical students pursuing a career in radiation oncology.

  1. Nabavizadeh N, Burt LM, Mancini BR, Morris ZS, Walker AJ, Miller SM, Bhavsar S, Mohindra P, Kim MB, Kharofa J; ARRO Executive Committee. Results of the 2013-2015 Association of Residents in Radiation Oncology Survey of Chief Residents in the United States. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):228-34. Epub 2015 Oct 22.PMID: 26853332
  2. Brower J, Mohindra P, Golden D, Bradley K. Radiation oncology residency selection: A targeted assessment of factor importance among fourth year medical students. Int J Radiat Oncol Biol Phys., 2014;88:967-968. PMID: 24606856
    1. Mattes M, Golden D, Mohindra P, Kharofa J, and the ARRO Education Subcommittee. Results of the 2013 Association of Residents in Radiation Oncology (ARRO) Career Planning Survey of Practicing Physicians in the United States. J Am Coll Radiol., 2014;11:817-823. PMID: 24709553
    2. Pranshu Mohindra, Steven P. Howard. ARROContour- Glioblastoma multiforme. Assoiation of Residents in Radiation Oncology (ARRO) Educational Resource.                                                                                https://www.astro.org/ARRO/Resident-Resources/Educational-Resources/ARROCase/index.aspx

Additional Publication Citations

Other peer-reviewed publications (total 28 peer-reviewed publications, 4 peer-reviewed online educational presentations, 28 published abstracts, multiple oral and poster conference presentations, 1 book chapter):

Google Scholar: 175 citations, h-index 8, i10-index 5

https://scholar.google.com/citations?user=qSgqHtIAAAAJ&hl=en

Research Gate: RG score 34.16

https://www.researchgate.net/profile/Pranshu_Mohindra

Research Interests

See Biosketch

Clinical Specialty Details

Dr. Mohindra provides patient care service for patients with thoracic/lung, gynecological and hemato-lymphoid malignancies. Dr. Mohindra is experienced in the latest radiation modalities including intensity modulated proton therapy (IMPT)/pencil beam scanning proton therapy, intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT) and Image-guided Brachytherapy.  

Awards and Affiliations

Professional Society Membership

  • 2005-present: Life Member, Association of Radiation Oncologists of India (AROI), ID: LM 883
  • 2006-2014: Member-in-training, ASTRO; ID 35192732
  • 2010-2014: Member-in-training, RSNA; ID 00435019
  • 2010-2014: Member-in-training, ACR; ID 05089204
  • 2010-2014: Member-in-training, ACRO; ID 28311
  • 2011-2014: Member-in-training, ASCO; ID 146438
  • 2012-2014: Associate Member, AACR; ID 251301
  • 2014-2015: Full Member, RRS
  • 2014-present: Affiliate Member, ASTRO; ID 35192732
  • 2015-present: Full Member, IASLC
  • 2015-present: Full Member, ACRO
  • 2016-present: Full Member, ABS

Honors And Awards

  • 1995: National top 0.1% merit list in ‘Science’ subject at All India Secondary School Examination
  • 1995: National Talent Search Examination Scholarship, India
  • 2000: Distinction [score more than 75%] in ‘Human Pathology’ in Board examinations of Medical school, University of Mumbai.
  • 2005: Best Poster, ESTRO International Symposium: ESTRO / TMH Evidence Based Medicine, Mumbai
  • 2006: All-India First Rank, Professional Diploma in Clinical Research, Class of October- 2006
  • 2007: Winner, Quiz; National Conference of Indian Cooperative Oncology Network (ICON), India
  • 2007: Invited Symposium Speaker at International Congress of Radiation Research [ICRR], San Francisco
  • 2007: Best thesis award, Indian Cooperative Oncology Network (ICON), India
  • 2008: UICC World Cancer Congress Travel Grant, Geneva, Switzerland
  • 2012: Fellowship Grant: AACR/ASCO Workshop on Methods in Clinical Cancer Research
  • 2014: ASTRO Spring Refresher Course Travel Grant, New Orleans, USA
  • 2013-14: Chief Resident, University of Wisconsin School of Medicine, Radiation Oncology, Wisconsin, USA
  • 2014: RSNA Roentgen Resident/Fellow Research Award, USA
  • 2014: ASTRO Resident Digital Poster Discussion Award (Biology Category), San Francisco, USA
  • 2014: Clinical Case Contest Winner (Senior Author). Applied Radiation Oncology, September 2014
  • 2014: Selection for the NCI’s Experimental Therapeutics Clinical Trials Network Career Development Project Team Member (VX-970 Brain Metastases). Principal Investigator on a NCI-sponsored multi-institutional study (Protocol # 9952) titled: “Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)”. CTEP “Approval on Hold” status, CIRB: Approval Pending Modification of Initial Review.
  • 2015: Appointed member, ACRRadiation Oncology In-Training (TXITTM) Exam-2016, Thoracic section
  • 2016: Appointed member, ACRRadiation Oncology In-Training (TXITTM) Exam-2016 Lymphoma and Gynecology section
  • 2016: Research Abstract as Senior Author selected for 2016 Best of Astro

Grants and Contracts

Department of Radiation Oncology R&D Seed grant, University of Wisconsin - 2013

Role: Study Chair (Primary contributor)/ Co-Investigator
Assessment of Human Papillomavirus (HPV) Status in Archived Tissue from Oropharyngeal Cancer Biopsies
Peer Reviewed, collaborative interdepartmental project with Department of Pathology
Total amount: $8,725 (no salary support)

  1. Barasch S, Mohindra P, Hennrick K, Hartig GK, Harari PM, Yang DT.Assessing p16 Status of Oropharyngeal Squamous Cell Carcinoma by Combined Assessment of the Number of Cells Stained and the Confluence of p16 Staining: A Validation by Clinical Outcomes. Poster presentation: USCAP Annual Meeting 2014; San Diego, CA: Lab Invest., 2014;94(S1):315A. Full Manuscript: Am J. Clin Path. Am J Surg Pathol. 2016 May 16. [Epub ahead of print]. PMID: 27186851.
  2. Mohindra P, Ibrahim N, Barasch S, Geye H, Yang DT, Perlman S, McCulloch T, Hartig G, Harari PM. Relative prognostic interplay of HPV status and PET scan maximum standardized uptake value (SUVmax) in squamous cell carcinoma of the oropharynx (SCC-OP) [abstract]. Int J Radiat Oncol Biol Phys., 2014:90(suppl):S193-S194. Digital poster with oral presentation: ASTRO 56th Annual Meeting 2014; San Francisco, CA.

Department of Radiation Oncology R&D Seed grant, University of Wisconsin - 2010-2013
Role: Co-investigator
SEER-medicare database analysis
Peer Reviewed, Total Amount: $15,885 (no salary support)

  1. Hong JC, Kruser TJ, Gondi V, Mohindra P, Cannon, D, Harari P, Bentzen S. Risk of cerebrovascular events in elderly patients following radiotherapy versus surgery for early-stage glottic cancer. Int J Radiat Oncol Biol Phys., 2013;87:290-296. PMID: 23906930

Department of Radiation Oncology Seed grant, University of Mayland School of Medicine, Baltimore - 2015
Role: Principal-investigator and Resident Mentor
Pediococcus–based Probiotics: A Murine Model to Assess Prevention and Mitigation of Radiation Induced Intestinal Toxicity (RiIT)
Peer Reviewed, collaborative inter-division project
Total amount: $10,764 (no salary support)
Ongoing study.

Department of Radiation Oncology Seed grant, University of Mayland School of Medicine, Baltimore - 2016
Role: Co-investigator
Nonuniform spatiotemporal fractionation for SAbR IMPT in central lung lesions
Peer Reviewed, collaborative inter-division project
Total amount: $12,000 (no salary support)
Ongoing study.

Professional Activity

Academic Administrative Roles

Institutional

  • 2013-2014: Chief Resident, Dept. of Radiation Oncology, University of Wisconsin Hospital and Clinics
  • 2013-2014: Peer-nominated member, Resident Quality and Safety Council, University of Wisconsin Hospital and Clinics
  • 2016-Present: Director of Research Internships, Department of Radiation Oncology, University of Maryland School of Medicine

National/ International

  • 2013-2016: Appointed member, American Society for Radiation Oncology (ASTRO): Funding Advocacy and Clinical Trials Committee [FACT] [formerly NIH Clinical Trials Committee]
  • 2016-Present: Appointed member, Alliance for Clinical Trials in Oncology-Symptom Intervention Committee, Radiation Oncology Committee, Leukemia Committee
  • 2016-Present: Member, NCI Brain Metastases Working Group
  • 2016-Present: Appointed member, American Society for Radiation Oncology (ASTRO):Research Grants Evaluation Subcommittee and Workforce Subcommittee

Reviewer Roles

Institutional

  • 2014: Judge (poster presentation), Medical Student Research Day, Office of Student Research, Alpha Omega Alpha Honor Society, University of Maryland School of Medicine
  • 2014-present: Residency Interview Selection Committee, Radiation Oncology, University of Maryland School of Medicine, Baltimore
  • 2014: Radiation Oncology Faculty Candidate Interview, University of Maryland School of Medicine, Baltimore
  • 2014: Nephrology Faculty Candidate Interview, University of Maryland School of Medicine, Baltimore
  • 2015: Cancer Review Committee (CRC) member, University of Maryland Greenebaum Cancer Center, Baltimore
  • 2016: Dosimetry Student Interview Selection Committee, Radiation Oncology, University of Maryland School of Medicine, Baltimore
  • 2016: Technology Research Review Committee (TRRC), Radiation Oncology, University of Maryland School of Medicine, Baltimore

National/ International

  • 2011-2014: Selected member and peer reviewer, Education Subcommittee, Association of Residents in Radiation Oncology (ARRO)
  • 2012-2014: Appointed member, Radiation Oncology panel, Education Exhibits Committee for RSNA Annual Meeting
  • 2013-present: Invited honorary editorial board member, Journal of Brain and Spinal Cancer
  • 2013-present: Journal reviewer, The Journal of Neurosciences in Rural Practice
  • 2014-present: Journalreviewer, RadioGraphics
  • 2014-present: Journalreviewer, International Journal of Radiation Oncology Biology Physics
  • 2015-present: Journalreviewer, Lung Cancer
  • 2016: Dutch Cancer Society (KWF) and Dutch Technology Foundation (STW): Partnership Research Programme-Technology in Oncology Reviewer of Grant Proposal
  • 2016: Abstract Reviewer, 2017 Multidisciplinary Thoracic Cancers Symposium